2020
Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance
Avitan-Hersh E, Feng Y, Oknin Vaisman A, Abu Ahmad Y, Zohar Y, Zhang T, Lee JS, Lazar I, Sheikh Khalil S, Feiler Y, Kluger H, Kahana C, Brown K, Ruppin E, Ronai ZA, Orian A. Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance. Journal Of Investigative Dermatology 2020, 140: 2466-2477. PMID: 32360601, PMCID: PMC8081033, DOI: 10.1016/j.jid.2020.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinogenesisCell Line, TumorDrug Resistance, NeoplasmEukaryotic Initiation Factor-2FemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMelanomaMiceMitogen-Activated Protein KinasesNuclear ProteinsOncogenesPrognosisProtein Kinase InhibitorsProtein StabilityProto-Oncogene Proteins B-rafSkinSkin NeoplasmsTranscription FactorsUbiquitinationXenograft Model Antitumor AssaysConceptsUbiquitin ligase RNF4Elongation factor alphaPatient-derived melanomasIntegrated stress responseTherapy resistancePositive feed-forward loopTranscription factor 4Feed-forward loopOncogenic translationMolecular machineryMajor clinical challengePhosphorylated eIF2αHallmark of melanomaXenograft mouse modelHomologous proteinsStress responseMAPK inhibitorProtein stabilizationMelanoma tumorigenesisTumorigenic propertiesPoor prognosisFactor alphaClinical challengeMouse modelRNF4
2016
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-2175. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellCell DedifferentiationDNA Mismatch RepairDNA-Binding ProteinsExomeFemaleGenes, p53HumansKidney NeoplasmsLoss of HeterozygosityMaleMiddle AgedMutationNuclear ProteinsOncogenesPolymorphism, Single NucleotidePrognosisTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseConceptsClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSarcomatoid elementsCarcinomatous elementsCell carcinomaSomatic single nucleotide variantsVon Hippel-Lindau tumor suppressorPoor-prognosis cancerTreatment of patientsTumor protein p53 (TP53) mutationsMismatch repair deficiencyRich interaction domain 1ASarcomatoid featuresPoor prognosisUnknown pathogenesisPolybromo-1TP53 mutationsP53 mutationsSarcomatoid transformationPan-cancer genesExome sequencingTumorsRepair deficiencyProtein 1
2012
Chapter One Vertical Pathway Targeting in Cancer Therapy
Shahbazian D, Sznol J, Kluger HM. Chapter One Vertical Pathway Targeting in Cancer Therapy. Advances In Pharmacology 2012, 65: 1-26. PMID: 22959021, DOI: 10.1016/b978-0-12-397927-8.00001-4.Peer-Reviewed Original ResearchConceptsVital cellular processesDifferent signaling pathwaysDNA maintenanceCellular processesCell divisionDrug combinationsSignaling pathwaysSame pathwayAdaptive responseParticular mutationCell proliferationRecent discoveryPathwayTypes of cancerFragile nodesAdditional targetsGrowth inhibitoryUnavoidable toxicitiesMutationsMultitarget inhibitionCytotoxic effectsCancer researchSolid tumorsProlonged responseMalignant cells